Sumitomo Pharma Co., Ltd.
4506住友ファーマ株式会社
Latest half-year results
First half · fiscal year to 2026-03 · filed 2025-11-04For the first half of the fiscal year to 2026-03: Revenue ¥227.1 billion (+25.7% YoY), Profit before tax ¥92.8 billion, Net income ¥98.9 billion.
| This period | Year on year | |
|---|---|---|
| Revenue | ¥227.1bn | +25.7% |
| Profit before tax | ¥92.8bn | — |
| Net profit to owners | ¥98.9bn | — |
From the securities report on EDINET, which states no forecast. History via /v1/companies/4506/earnings-releases.
Financials
IFRS · consolidated · fiscal year to 2026-03-31- Revenue
- ¥453.3bn
- Net income
- ¥106.9bn
- ROE
- 46.3%
- Equity ratio
- 36.4%
- Dividend / share
- —
- Employees
- 3,123
| Fiscal year | Revenue | Net income | Total assets | Net assets | ROE | EPS | Operating CF |
|---|---|---|---|---|---|---|---|
| 2026-03-31 | ¥453.3bn | ¥106.9bn | ¥804.6bn | ¥292.5bn | 46.3% | ¥268.99 | ¥71.7bn |
| 2025-03-31 | ¥398.8bn | ¥23.6bn | ¥742.6bn | ¥169.5bn | 14.5% | ¥59.49 | ¥16.5bn |
| 2024-03-31 | ¥314.6bn | −¥315.0bn | ¥907.5bn | ¥156.1bn | -111.9% | ¥-792.79 | −¥241.9bn |
| 2023-03-31 | ¥555.5bn | −¥74.5bn | ¥1,134.7bn | ¥406.7bn | -14.7% | ¥-187.55 | ¥11.9bn |
| 2022-03-31 | ¥560.0bn | ¥56.4bn | ¥1,308.0bn | ¥607.9bn | 9.5% | ¥141.99 | ¥31.2bn |
Indicators
Computed by us from filings · fiscal year to 2026-03-31| Metric | Value | Percentile among listed companies |
|---|---|---|
| ROE, % | 46.3 | 98.8 |
| Ordinary margin | 0.2214 | 92.4 |
| Equity ratio, % | 36.4 | 22.1 |
| Revenue growth | 0.1366 | 77.6 |
| Net income growth | 3.5217 | 96.4 |
| Operating cash flow / assets | 0.0891 | 67 |
Results wording balance: +0.40. Proprietary text method; it describes the wording only and does not interpret context.
Interest example: if all ¥217.2bn of reported debt repriced by 50 basis points, a year's interest would rise by ¥1.1bn, 1.5% of operating cash flow. Our arithmetic only, not a forecast: fixed-rate debt and hedges are ignored.
Via /v1/companies/4506/indicators. Descriptive figures, not a rating and not investment advice.
From other filings
As the company states themSegments, votes and tender offers
Stated in EDINET filings/v1/companies/4506/segments/v1/companies/4506/votingOwnership changes
All companies →- 2026-06-05
SMBC Nikko Securities Inc. cut holdings in Sumitomo Pharma Co., Ltd. (4506) to 3.23% from 6.06%, below the 5% threshold.
- 2026-05-12
SMBC Nikko Securities Inc. disclosed a 6.06% stake in Sumitomo Pharma Co., Ltd. (4506), crossing the 5% reporting threshold.
5% filings
Large shareholding reports on 4506| Filed | Filer | Stake | Change | Stated purpose |
|---|---|---|---|---|
| 2026-06-05 | SMBC Nikko Securities Inc. | 3.23% | −2.83pt | — |
| 2026-05-12 | SMBC Nikko Securities Inc. | 6.06% | — | — |
| 2026-04-23 | SUMITOMO CHEMICAL COMPANY, LIMITED | 51.68% | 0.00pt | business alliance |
| 2023-06-05 | SUMITOMO CHEMICAL COMPANY, LIMITED | 51.68% | 0.00pt | business alliance |
Cross-shareholdings
From the annual report's status of shareholdings- Listed strategic holdings
- 4 issues
- Book value
- ¥2.4bn
- Sold in the year
- ¥3.2bn 3 issues
- Bought in the year
- — — issues
- Mutual, both reports
- 3
- Held by listed cos.
- 10
| Holds | Book value | Shares vs. prior year | Mutual |
|---|---|---|---|
| Sumitomo Mitsui Financial Group, Inc. 8316 | ¥11.1bn | 0.0% | no |
| Mitsubishi UFJ Financial Group, Inc. 8306 | ¥7.2bn | 0.0% | no |
| Mochida Pharmaceutical Co.,Ltd. 4534 | ¥1.9bn | 0.0% | both reports |
| 株式会社ほくやく・竹山ホールディングス | ¥0.4bn | 0.0% | stated |
| Sharp Therapeutics Corp. | ¥0.1bn | 0.0% | no |
| FunPep Company Limited 4881 | ¥0.0bn | 0.0% | no |
| VITAL KSK HOLDINGS,INC. 3151 | — | sold all | both reports |
| MEDIPAL HOLDINGS CORPORATION 7459 | — | sold all | both reports |
| 広栄化学株式会社 4367 | — | sold all | no |
Held by: Inabata&Co.,Ltd. 8098, MS&AD Insurance Group Holdings, Inc. 8725, Mochida Pharmaceutical Co.,Ltd. 4534, TSUMUGU Holdings, Inc. 3055, VITAL KSK HOLDINGS,INC. 3151, SUZUKEN CO.,LTD. 9987, VITAL KSK HOLDINGS,INC. 3151, Astena Holdings Co., Ltd. 8095, VITAL KSK HOLDINGS,INC. 3151, Riken Vitamin Co., Ltd. 4526, MEDIPAL HOLDINGS CORPORATION 7459, TOHO HOLDINGS CO.,LTD. 8129
Purposes, all holdings and mutual flags via /v1/companies/4506/cross-holdings. Share changes include stock splits.
Major shareholders
As of fiscal year end 2026-03-31| Shareholder | Shares | Ratio |
|---|---|---|
| 住友化学株式会社 | 205,634,000 | 51.76% |
| 日本マスタートラスト信託銀行株式会社（信託口） | 25,038,000 | 6.30% |
| 株式会社SMBC信託銀行（株式会社三井住友銀行退職給付信託口） | 7,000,000 | 1.76% |
| 株式会社日本カストディ銀行（信託口） | 6,219,000 | 1.57% |
| 住友生命保険相互会社 | 5,776,000 | 1.45% |
| individual holder | 4,573,000 | 1.15% |
| 稲畑産業株式会社 | 4,400,000 | 1.11% |
| THE BANK OF NEW YORK, TREATY JASDEC ACCOUNT | 3,977,000 | 1.00% |
| 日本生命保険相互会社 | 3,790,000 | 0.95% |
| J.P. MORGAN BANK LUXEMBOURG S.A. 381593 | 3,030,000 | 0.76% |
U.S. funds holding 4506
SEC Form N-PORT, reports to 2026-07-3159 U.S. funds held 17,603,431 shares worth $146.6m.
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| VANGUARD TOTAL INTERNATIONAL STOCK INDEX FUND VANGUARD STAR FUNDS | 3,336,107 | $26.0m | 0.004% | 2026-07-31 |
| VANGUARD DEVELOPED MARKETS INDEX FUND VANGUARD TAX-MANAGED FUNDS | 2,244,601 | $20.8m | 0.007% | 2026-06-30 |
| T. Rowe Price International Discovery Fund T. ROWE PRICE INTERNATIONAL FUNDS, INC. | 2,182,300 | $17.0m | 0.255% | 2026-07-31 |
| iShares Core MSCI EAFE ETF iShares Trust | 1,718,000 | $13.4m | 0.007% | 2026-07-31 |
| College Retirement Equities Fund - Total Global Stock Account College Retirement Equities Fund | 1,282,100 | $11.9m | 0.008% | 2026-06-30 |
Up to 25 funds per stock via the API.
Get this as JSON
GET /v1/companies/4506
GET /v1/companies/4506/financials
GET /v1/companies/4506/details
GET /v1/companies/4506/segments
GET /v1/companies/4506/voting
GET /v1/companies/4506/tender-offers
GET /v1/companies/4506/indicators
GET /v1/companies/4506/earnings-releases
GET /v1/events?ticker=4506
GET /v1/companies/4506/trades
GET /v1/companies/4506/cross-holdings
GET /v1/companies/4506/brief